Stock screenerAll disclosures →
EDGAR →
QURE
Conviction 63HealthcareScan · Mon, Aug 10, 2026QURE$46.05-0.80%
ResistanceSupportVol 14Insider sell3
2
10
Vol MA14 1.59M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price46.05
Change-0.80%
Gap-1.22%
Rel volume0.58×
Avg volume1.42M
Avg $ vol58.42M
SMA 2041.56
SMA 5039.14
SMA 20028.06
Price vs 50+17.66%
Price vs 200+64.14%
MA stackbullish
50/200 cross—
Supertrendup · 39.21
RSI (14)65
MACD hist0.44
MACD crossbull · 5d
Stoch %K / %D84 / 90
ADX (14)17
+DI / −DI31 / 18
RSI divergence—
MACD divergenceBullish
ATR %+5.31%
ADR %5.16%
52w high70.59
52w low9.03
From 52w high-34.76%
Above 52w low+409.97%
New 52w highNo
SqueezeOff
Bollinger width25.77%
%B0.92
Donchian pos83.90%
Donchian high48.11
Donchian low35.34
AVWAP (52w high)26.10
vs AVWAP high+76.44%
AVWAP (52w low)27.02
vs AVWAP low+70.44%
OBV trendUp
Chaikin MF (20)0.03
Today vs 20d0.58×
Avg vol (14d)1.59M
Avg vol (20d)1.42M
Avg $ vol (20d)58.42M
Market cap2.9B
RS 3m (vs SPY)+86.52%
RS 6m (vs SPY)+75.20%
RS line new highNo
Trend template4/8
Technical rank92.3
1 week+4.52%
1 month+8.02%
3 months+66.49%
6 months+79.53%
1 year+242.38%
YTD+96.88%
P/E-14.60
P/B19.45
P/S—
P/FCF-16.28
EPS-3.46
Div yield—
ROE-133.23%
ROA-25.55%
Debt/Eq0.41
Current10.40
EV/EBITDA-16.56
Gross margin—
Net margin—
Rev growth—
EPS growth16.94%
Price target65.63
Target upside42.52%
Analyst ratingBuy
Institutional86.54%
Ent. value2.83B
Revenue3.56M
Net income-53.53M
Gross profit—
Free cash flow-178.4M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out63.07M
Employees221
ListedWed, Feb 5, 2014
Free float55.88M
Float %89.4%
Short interest10.37M
Days to cover7.1d
Short volume40.0%
Squeeze score62 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.22 vs −$0.81
Last surprise-50.6% miss
Setup gradeB
Conviction63 / 100
Pattern quality—
Tech rank92.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance50.28
Support31.00
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in QURE
No recent disclosed trades by Congress in QURE. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in QURE · 2 buys · 8 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Exercise | 21.08K | $409K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 9.2K | $409K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 4.28K | $195K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-07-02 | Sell | 7.6K | $349K | 2026-07-02 | 2026-07-07 |
Kapusta Matthew C CEO, Managing Director · Stock Option (Right to Buy) · 2026-07-02 | Exercise | 21.08K | — | 2026-07-02 | 2026-07-07 |
Abi-Saab Walid Chief Medical Officer · Ordinary Shares · 2026-06-26 | Sell | 1.43K | $67K | 2026-06-26 | 2026-06-30 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Exercise | 4.66K | $148K | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Stock Option (Right to Buy) · 2026-06-18 | Exercise | 4.66K | — | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Sell | 4.66K | $233K | 2026-06-18 | 2026-06-22 |
Kapusta Matthew C CEO, Managing Director · Ordinary Shares · 2026-06-18 | Sell | 37.02K | $1.9M | 2026-06-18 | 2026-06-22 |
SEC filings
EDGAR filings in QURE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.